Sleeve Gastrectomy in Metabolic Syndrome for Nonmorbid Obese Patients: Is this the Future for Diabetes Treatment?

Résumé fourni par la source

During the development of surgical treatments, there have been so many improvements and challenging task that have lead surgeons to treat patients with new procedures and new indications. Gastrectomy surgery initially was performed for cancer surgery. Now it is a worldwide performed procedure for complete healthy stomachs, but the main indication its weight loss, and all the physiological improvements that this procedure will bring to the patients’ health. During the bariatric surgery development, there have been different choices for different indications and different patients, depending on a variety of conditions and data that take evidence based medicine, to approve that this procedures can be accepted in the surgical field. All the studies that have been showing improvement of medical conditions in obese patients, and had compared different type of procedures (Gastric Bypass, Duodenal Switch, Biliopancreatic Divertion, Sleeve Gastrectomy), led surgeon in different part of the world to take indications of surgery beyond weight loss. Being proved by previous analysis, that most of the patients get remission or cure, of comorbidities before an statistically significant weight loss, this study was led to perform vertical sleeve gastrectomy in patients with overweight, nonobese, that where diagnosed with metabolic syndrome (MS). Ten patients where operated (f = 6 m = 4), all of them met at least three criteria for MS (National Cholesterol Education Program Adult Treatment Panel III Citeria), 100% had diabetes mellitus (DM) as a criteria. After surgery the patients where followed up to 12 months and the mean body mass index (BMI) achieved overall was 22.58 kg/m 2 being the minimum 18.8 kg/m 2 (f = 22.28 m = 22.44). The total mean weight loss overall was 64.95 ± 12.6 kg, and the mean percentage of weightloss was 35% of initial weight with no clinical significance in the patients and 70% had remission of DM.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.